The article offers information on the impact of the Anti-Counterfeiting Trade Agreement (ACTA) on pharmaceutical companies. It mentions the key provisions of ACTA and the impact of third-party enforcement on access to medicines. It presents the third-party enforcement and intermediary application of ACTA to pharmaceutical companies.